NDAORALSOLUTIONPriority Review
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIAGEN (abacavir sulfate) is an oral nucleoside reverse transcriptase inhibitor (NRTI) approved for HIV treatment. It works by inhibiting HIV reverse transcriptase, reducing viral replication in infected patients. This small-molecule antiretroviral is typically used as part of combination antiretroviral therapy (cART) for HIV-1 infection.
LOE Approaching
As a mature product approaching loss of exclusivity, ZIAGEN teams are likely focused on cost management and lifecycle extension rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers
Started Mar 2014
18 enrolled
Psoriasis
ZIAGEN® Post-marketing Surveillance
Started Nov 2010
671 enrolled
Infection, Human Immunodeficiency Virus I
Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
Started Feb 2004
54 enrolled
HIV Infections
Career Relevance
Working on ZIAGEN offers limited career growth in traditional commercial roles; opportunities are concentrated in managed care, reimbursement defense, and supply-chain optimization as the product approaches LOE. This role suits professionals seeking stability in a legacy brand rather than high-growth promotional positions.
Worked on ZIAGEN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.